T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
OXFORD, United Kingdom, and CAMBRIDGE, Mass., April 05, 2018 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces that Glyn Edwards, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference on 10 April 2018 at 3:00pm CEST in Monte Carlo, Monaco.
A live audio webcast of the presentation will be available through the Investors section on the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer | ||
| Panmure Gordon (Joint Broker) | Tel: | +44 (0)20 7886 2500 |
| Freddy Crossley, Corporate Finance | ||
| Tom Salvesen, Corporate Broking | ||
| MacDougall Biomedical Communications (US) | Tel: | +1 781 235 3060 |
| Karen Sharma | [email protected] | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Jessica Hodgson / | [email protected] | |
| Philippa Gardner |
